Table 2.
Persistence rates and 95% CIs
| Biologic agents | Overall, % (95% CI)
|
Biologic-naïve patients, % (95% CI)
|
Biologic-continuing patients, % (95% CI)
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months | 12 months | 18 months | 6 months | 12 months | 18 months | 6 months | 12 months | 18 months | |
| Etanercept | 87.5 (85.2–89.5) |
79.5 (76.7–81.9) |
70.6 (67.5–73.5) |
97.9 (86.1–99.7) |
89.6 (76.7–95.5) |
86.6 (72.3–93.8) |
86.9 (84.5–89.0) |
78.9 (76.0–81.5) |
69.8 (66.6–72.8) |
| Adalimumab | 91.1 (87.8–93.6) |
84.3 (80.3–87.6) |
78.7 (74.2–82.6) |
100 | 96.9 (79.8–99.6) |
96.9 (79.8–99.6) |
90.3 (86.7–92.9) |
83.2 (78.8–86.7) |
77.2 (72.4–81.2) |
| Infliximab | 95.8 (93.8–97.2) |
93.5 (91.2–95.3) |
91.5 (88.9–93.6) |
98.8 (91.8–99.8) |
97.6 (90.7–99.4) |
97.6 (90.7–99.4) |
95.3 (93.0–96.8) |
92.8 (90.2–94.8) |
90.5 (87.5–92.8) |
| Golimumab | 93.9 (87.6–97.0) |
91.2 (84.3–95.2) |
85.6 (77.5–90.9) |
100 | 100 | 100 | 91.9 (83.7–96.1) |
88.5 (79.7–93.6) |
81.5 (71.6–88.2) |
| Tocilizumab | 94.5 (91.8–96.4) |
89.1 (85.6–91.8) |
84.2 (80.2–87.4) |
98.0 (86.6–99.7) |
96.0 (84.9–98.9) |
93.7 (81.7–97.9) |
94.5 (91.0–96.1) |
88.1 (84.2–91.1) |
82.8 (78.5–86.4) |
| Abatacept | 96.8 (92.6–98.7) |
95.6 (90.9–97.9) |
94.9 (90.0–97.4) |
96.8 (79.8–99.6) |
93.7 (77.2–98.4) |
93.7 (77.2–98.4) |
96.8 (91.8–98.8) |
96.0 (90.7–98.3) |
95.2 (89.6–97.8) |
Abbreviation: CI, confidence interval.